Top Markets
#1 CoW Protocol CoW Protocol +65.62%
#2 EXOD EXOD +56.80%
#3 Glidr Glidr +35.94%
#4 Cysic Cysic +24.17%
#5 Nockchain Nockchain +15.44%
#6 Velvet Velvet +15.00%
#7 Humanity Humanity +14.65%
#8 The Black Bull The Black Bull +13.24%
#9 Tutorial Tutorial +12.75%
#10 Versatize Coin Versatize Coin +12.49%
Coin of the day
CoW Protocol CoW Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
Peak Bio, Inc. Peak Bio, Inc.

Peak Bio, Inc.

PKBO
Rank in Stocks #37553
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical... Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.
Share Price
$0.07
Last synced: 2024-11-12
Market Cap
$1.62M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Peak Bio, Inc. (PKBO)

Category

Healthcare
Revenue for Peak Bio, Inc. (PKBO)
Revenue in Aug 2026 TTM: 0
According to Peak Bio, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Peak Bio, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE